Search PubMed⌕ Search

Biomedical subjects

C Trepo

Publications and source records attributed to C Trepo.

At least 289 records · Page 16Linked to original sources
PubMed1977

A counterimmunoelectrophoretic technique for the detection of HBeAg/anti-HBeAg (e antigen/antibody) in human sera.

A counterimmunoelectrophoretic technique is presented for the serological detection of the e system. Counterimmunoelectrophoresis was found reproducible and easy to perform; it is quicker and more sensitive than immunodiffusion since out of 243 HBSAg positive carriers, it detected HBeAg or anti-HBe in other 42 (17.3%) sera in addition to the 96 positive by immundiffusion.

Antibodies, Viral↗
PubMed1977

[Fine-needle percutaneous transhepatic cholangiography. 84 cases].

The authors report the results of 84 percutaneous transhepatic cholangiographies using a fine needle, describing the technique. Beyond the context of jaundice, failure of or inadequate opravenous cholangiography requires the use of other radiological techniques. By virtue of its simplicity, its usually good tolerance and its results, percutaneous transhepatic cholangiography has a place of choice in these indications. Its value in comparison with other non-surgical methods of direct opacification of the biliary tract is discussed.

Bile Ducts, Intrahepatic↗
PubMed1977

[Periarteritis nodosa and Australia antigen. Comparative study apropos of 25 cases].

The authors compared two series of 27 cases of périateritis over a period of 5 years. The determined the frequency of the nodosa HBs+ (series B) and HBs-- (series A) collected clinical and laboratory signs in both series. There resulted that apart from the hepatic signs constant in series B and absent in series A, the only statistically significant differences were the joint sings and the hypertension more common in series B and the respiratory signs more common in series A. Furthermore, the course of HBs+ cases appears much mote severe than that of HBs-- cases which emphasises the importance of the hepatic involvement but this finding should be interpreted with circumspection for the mode of selection of the patients and the treatment were different in the two series.

Adolescent↗
PubMed1977

The e antigen and vertical transmission of hepatitis B surface antigen.

The relationship of e antigen (eAg) and its antibody (anti-e) to vertical transmission of hepatitis B surface antigen (HBsAg) from chronic asymptomatic HBsAg carrier women to their children was investigated in Taiwan. Sera from 20 of the 62 women studied were positive for eAg (32%); serum from only one woman was positive for anti-e (2%). A total of 85% of the babies born to eAg positive mothers became HBsAg carriers, while only 31% of the babies became carriers when the mother was eAg negative. Maternal e antigenemia correlated with a high HBsAg titer, and both parameters were equally good predictors of vertical transmission.

Aspartate Aminotransferases↗
PubMed1977

Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers.

A new antigen-antibody system associated with the hepatitis B virus and immunologically distinct from the HB surface, core, and e systems is reported. The new antigen, termed delta, was detected by direct immunofluorescence only in the liver cell nuclei of patients with HBsAg positive chronic liver disease. At present, the intrahepatic expression of HBcAg and delta antigen appears to be mutually exclusive. No ultrastructural aspect corresponding to the delta antigen could be identified under the electron microscope. delta antibody was found in the serum of chronic HBsAg carriers, with a higher prevalence in patients with liver damage. The nuclear fluorescence patterns of HBcAg and delta antigen were similar; it is only possible to discriminate between the two antigens by using the respective specific antisera.

Adult↗
PubMed1977

Correlations between the detection of e antigen or antibody and electron microscopic pattern of hepatitis B surface antigen (HBsAg) associated particles in the serum of HBsAg carriers.

The distribution of HBsAg associated particles, especially the presence of Dane particles, was studied by electron microscopy in coded sera of 68 chronic HBsAg carriers. Results were correlated with the detection of eAg or Ab and clinical diagnosis. Sera from haemodialysis and chronic hepatitis patients showed a high prevalence of e antigenaemia (9/13, 69-2% and 8/19, 42-1%) and Dane particles (11 and 16 respectively, 84%). By contrast, out of 36 chronic asymptomatic carriers of HBsAg, 28 (77-7%) were positive for e antibody but only 1 (2-7%) had eAg. Dane particles were found in 13/36 (36-1%). A statistically significant correlation was observed between the detection of eAg and the presence of Dane particles (94-4%) in the serum. However, Dane particles were still observed in 10/28 (35-7%) of anti-e positive sera. The data suggest that eAg may be linked to complete HB virions.

Antibodies↗
PubMed1977

[Comparative study of three technics of inverse passive hemagglutination in the search for a surface antigen of the hepatitis b virus (Ag HBs) (author's transl)].

The following three different versions of reverse passive hemagglutination (RPHA) were evaluated for the detection of HBs antigen: Auscell I - Abbott, WH HBs - Wellcome and the hepanosticon - Organon technique and results obtained were compared with those obtained by the radio immuno assay (Ausria II of Abbott). In 493 sera studied, up to 16,8% were found positive by RPHA as compared to 17,2% positives by RIA. The percentage of false positives by the different methods varied from 4,9 to 7,3. Confirmatory tests, either absorption or neutralization, are necessary to ascertain accuracy of positive results in each of the 3 RPHA methods. The high quality of the Auscell and WH HBs confirmative test allows their sole use although they are slightly less sensitive than the RIA. We would recommand use of the Hepanosticon test whenever positive sera can be confirmed by RIA.

Evaluation Studies as Topic↗
PubMed1977

[Adult papular acrodermatitis (Gianotti's disease). Report of 3 cases].

The authors report three cases of adult papular acrodermatitis with circulating HBs antigen. The eruption was followed by a benign icteric hepatitis which lasted from 30 to 45 days. In two cases, HBs antigen disappeared in a one month period, in one case the antigen has been present for more than three months. Direct immunofluorescence staining exhibits c3 deposits in the vessels of the dermal lesions, without any deposition of immunoglobulins or fibrinogen. We were unable to demonstrate the presence of HBs and " e " antigens in the skin lesions (using FITC conjugated specific antiserums). Serum protein concentrations of complement components C1q, C4,C3, C3PA were normal as measured by radial immunodiffusion. The percentage of circulating B and T cells was normal, as essayed by E-RFC, EAC-RFC and sIg. Thus, adult papular acrodermatitis, as well as the infantile form, does represent a sign of invasion of a benign viral hepatitis.

Acrodermatitis↗
PubMed1976

Identification of additional antigenic sites on Dane particles and the tubular forms of hepatitis B surface antigen.

Additional antigenic sites, distinct from those present on spherical 20 nm diam. particles of hepatitis B surface antigen (HBsAg), are exposed on the surface of Dane particles and tubular forms of HBsAg. The immunological relationship of these sites to e-antigen, an antigen detected earlier in HBsAg-positive sera from patients with chronic hepatitis, cirrhosis or acute hepatitis but not in healthy HBsAg-carriers, was established by immune electron microscopy and affinity chromatography. These findings suggest that e-antigen may be potentially useful in active immunization against hepatitis B.

Acute Disease↗
PubMed1975

Some considerations regarding active immunization with HBsAg.

Krugman has demonstrated that injection of heated serum containing HBsAg conferred some protection against subsequent challenge with live hepatitis B virus (HBV). It is likely that improved protection will result from injections for larger quantities of HBsAg. This can be readily done with purified antigen. We have carried out preliminary studies in mice to investigate the inactivation kinetics of HBsAg antigenicity and immunogenicity. Rates of inactivation of the two parameters by heat have been found to be parallel. Chimpanzees will be required to determine adequacy of inactivation procedures, and optimal dose and immunization schedule, prior to the initiation of human trials. The use of newly imported chimpanzees for this purpose may be hazardous. Of 27 chimpanzees recently tested in an exporter's compound in Sierra Leone, ten were found to circulate HBsAg and five additional had detectable anti-HBs, suggesting a high risk of hepatitis B transmission within the compound. Thus newly imported animals may be incubating HB infection, and could give rise to false positive results in inactivation trials, unless quarantined for a four to six month period prior to use. We have therefore established a laboratory for chimpanzee trials in West Africa, and plan to utilize only animals captured by trapping and held in strict isolation from the time of capture. It is unlikely that immunization against HBV will ever provide absolute immunity. Three chimpanzees who received a massive transfusion of infective plasma one year after resisting challenge with aliquots of the same plasma inoculated intraperitoneally, all developed severe hepatitis, accompanied in two cases by HBs antigenemia, despite strong anamnestic anti-HBs responses in all three animals.

Animals↗